<DOC>
	<DOCNO>NCT00996606</DOCNO>
	<brief_summary>This open-label , single-arm study evaluate efficacy safety tocilizumab combination DMARDs participant moderate severe active rheumatoid arthritis inadequate response DMARDs . Participants receive tocilizumab 8 milligram per kilogram ( mg/kg ) via intravenous ( IV ) infusion every 4 week addition current DMARD therapy .</brief_summary>
	<brief_title>A Study Tocilizumab Combination With Disease-Modifying Anti-Rheumatic Drugs ( DMARDs ) Participants With Moderate Severe Active Rheumatoid Arthritis With Inadequate Response DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Moderate severe active RA ≥6 month duration DAS28 &gt; 3.2 Inadequate response stable dose nonbiologic DMARD ≥2 month Those receive oral corticosteroid must stable dose ≥25 day 28 day prior first study treatment Rheumatic autoimmune disease RA History current inflammatory joint disease RA Previous treatment alkylating agent total lymphoid irradiation Intraarticular parenteral corticosteroid within 6 week prior Baseline Previous treatment celldepleting therapy American College Rheumatology ( ACR ) Functional Class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>